Results 151 to 160 of about 7,402 (202)

Inhibition of OATP1B1/3 Rather Than UGT1A1 May Be the Major Cause of the Bilirubin Elevation After Atazanavir Administration. [PDF]

Clin Pharmacol Ther
Dong J, Sharma P, Emara R, Cheung D, Tang W, Zhou D, Boulton DW, Någård M, Park MS.   +8 more
europepmc   +1 more source

Optimising antiretroviral therapy through a proactive treatment algorithm: a cost-effective strategy in Dutch healthcare for people with HIV. [PDF]

J Antimicrob Chemother
Oosterhof P, van Luin M, Grintjes K, van der Meche N, van Crevel R, Brinkman K, Burger DM.   +6 more
europepmc   +1 more source

Statin Therapy as Primary Prevention for Persons With HIV: A Synopsis of Recommendations From the U.S. Department of Health and Human Services Antiretroviral Treatment Guidelines Panel. [PDF]

Ann Intern Med
Beavers C, Pau AK, Glidden D, Hyle E, Kuriakose S, Martin SS, McComsey G, Thompson M, Virani S, Baker JV.   +9 more
europepmc   +1 more source

Interaction of CYP3A4 with the inhibitor cobicistat: Structural and mechanistic insights and comparison with ritonavir. [PDF]

Arch Biochem Biophys
Sevrioukova IF.
europepmc   +1 more source

Vancomycin-Induced Severe Neutropenia in a Patient With Osteomyelitis: A Case Report. [PDF]

Cureus
Majeed I, Khan ZR, Harting J, Armes L, Arnold FW.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Rezolsta® (Darunavir/Cobicistat): First Boosted Protease Inhibitor Co-formulated with Cobicistat.

AIDS reviews, 2016
Rezolsta® (darunavir/cobicistat) is the first boosted protease inhibitor in a fixed-dose combination to be approved for the treatment of HIV infection. It contains darunavir, a protease inhibitor with a well-known safety and efficacy profile, and the new pharmacokinetic enhancer cobicistat.
Adrián, Curran, Ignacio, Pérez-Valero, José, Moltó   +2 more
openaire   +1 more source